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The overall aim of this systems change project is to identify the specific barriers to 
optimal care faced by Certified Registered Nurse Anesthetists (CRNAs) who are managing the 
pain of opioid tolerant patients, so as to eliminate those barriers. 
The postoperative pain of opioid tolerant patients is substantially undertreated, implicitly 
requiring changes in their treatment for both ethical and economic reasons.  These changes will 
require growth in CRNA skills and thinking.  Benner’s conceptual framework has been used to 
describe this growth in opioid tolerant pain management from novice to expert.  
A literature review informed the formulation of a descriptive survey instrument to gather 
data on the self-perceived barriers to optimal practice.  The questionnaire was distributed via the 
American Association of Nurse Anesthetists (AANA) to 2500 practicing CRNAs, achieving a 
question response rate of 25.6% (640) to 28.9% (717), yielding a very large sample size for each 
question.  The survey data were summarized and analyzed to distinguish the several actual from 
the numerous possible barriers.  
The analyses of the survey results revealed three barriers above all others: (a) a lack of 
specific guidelines for opioid tolerant patients, (b) a general failure to use an opioid calculator to 
ensure proper dosing, and (c) the very broadly-perceived need for CEUs specifically for 
managing the pain of the opioid tolerant patient.  To initiate the change process, this study was 
presented to members of the Minnesota Association of Nurse Anesthetists.  The data and 
analysis will serve as a font from which future researchers will draw. 
Keywords: Opioid tolerant, Certified Registered Nurse Anesthetist, CRNA, pain 
management, preemptive, multimodal 




Chapter One: Introduction 
This system change project lays a foundation of information intended ultimately to help 
Certified Registered Nurse Anesthetists (CRNAs) and other anesthesia providers reduce 
perioperative pain for their opioid tolerant patients.  The information was acquired via surveying 
a random sample of 2500 CRNAs to identify self-perceived barriers to optimal perioperative 
pain management for the opioid tolerant.  The problem of opioid tolerant pain and its 
management has yielded many studies from the perspectives of nursing and anesthesiology, but 
to date none have looked at this problem from a CRNA perspective.  Identifying which barriers 
CRNAs consider most common and significant will help in formulating systemic changes that 
will mitigate such barriers and thereby yield better outcomes for this unique patient population. 
Significance of the Problem 
Despite significant efforts, postoperative pain remains common—up to 70% of 
postoperative patients complain of moderate or severe pain (Pyati & Gan, 2007)—and under-
treated (Brennan, Carr, & Cousins, 2007).  Apfelbaum, Chen, Mehta, and Gan (2003, p. 537) 
noted that 73% of hospitalized surgery patients surveyed reported pre-discharge pain, with 88% 
of those reporting moderate to extreme pain.  Because trauma to the body during surgery may be 
very great, the resultant postoperative pain can be severe.  Other painful stimuli such as disease, 
injury, and inflammation can add to the suffering of a patient who is often in a very vulnerable 
state.  
Concretely, the anesthesia provider is often a CRNA, and the primary means of 
alleviating pain is opioid medication. Despite the many difficulties involved, as Brennan et al. 




(2007) noted, the anesthesia provider has a duty to provide pain relief: “pain management is 
required within the highest professional standards” (p. 214).   
 Opioids at the proper dosage typically relieve pain remarkably well.  Unfortunately the 
optimum dosage varies widely due to differences not only in inherent pain levels but also to 
opioid tolerance and opioid-induced hyperalgesia, which results from prior opioid exposure.  If 
the need for pain relief imposes a minimum opioid dosage, side effects and over-dosage impose a 
maximum risk—even while each of these levels commonly varies dramatically from patient to 
patient. 
Healthcare economics of suboptimal pain management.  
While economics is not always a central concern from an individual patient or clinician 
perspective, it is highly significant from a social perspective.  In the contexts of cost-
minimization and cost-effectiveness, management of pain in opioid tolerant patients presents a 
challenge to health care professionals (Asche, Seal, Jackson, & Oderda, 2006).  As a result of 
undertreated pain, the time spent in the recovery room and in the hospital is significantly 
increased (Dunwoody, Krenzischek, Pasero, Rathmell, & Polomano, 2008), further increasing 
the cost.  Moreover, it is well documented that other complications resulting from undermanaged 
pain include myocardial ischemia and myocardial infarction (Dunwoody et al, 2008), and 
increase the heart rate, blood pressure, and oxygen consumption (Spacek, 2006; Lewis, Whipple, 
Michael, & Quebberman, 1994).  Furthermore, a retrospective study conducted by Coley, 
Williams, DaPos, Chen, and Smith (2002), documented undermanaged pain as a major reason 
for readmission of patients thereby increasing costs (Coley et al., 2002).  Undermanaged pain 
also results in lower patient satisfaction (Koo, 2007), further impacting the economics.  
Therefore, it is imperative to manage pain optimally to benefit both the patient and the economy. 




Statement of the Problem. 
Pain is complex, pain management even more so, and pain management for opioid 
tolerant patients perhaps most of all.  In so difficult a challenge, every significant barrier to 
optimal care must be discovered and removed.  This systems change project queries a large 
random sample of CRNAs to identify barriers to optimal pain management for opioid tolerant 
patients, which is the first critical step to removing them. 
Background 
Anesthesia care for patients is commonly provided by a CRNA.  While it is generally 
acknowledged that nurse anesthetists were practicing as early as the mid-to-late 19
th
 century, 
formally credentialed CRNAs first appeared in 1945. Today, according to the American 
Association of Nurse Anesthetists (AANA), CRNAs safely and effectively administer anesthesia 
to approximately 32 million people every year in the United States (AANA, 2011).  CRNAs are 
the primary anesthesia providers in many rural settings for obstetrical, trauma, and surgical 
procedures.  In urban and suburban settings, CRNAs more often provide anesthesia in 
collaboration with anesthesiologists.   
CRNA education.  
As noted by the AANA (2011), prospective CRNAs must be licensed registered nurses 
with a minimum of a bachelor’s of science in nursing (BSN) or other sufficient baccalaureate 
degree and at least one year of acute care experience.  CRNA education proper requires a degree 
(e.g., Master’s of Nurse Anesthesia) from an accredited graduate school, typically taking 24-36 
months, combined with university- or community-hospital-based clinical training.  The total 
required education is approximately 7 years.  The average student nurse anesthetist works for at 
least 2,500 clinical hours while handling 850 anesthetic cases.  Approximately 2000 students 




graduate each year.  CRNAs are required to maintain their certification status by completing a 
minimum 40 continuing education credits every two years (Foster & Faut-Callahan, 2001). 
The most advanced training recognized is the doctor of nursing practice degree (DNP) 
(American Association of Colleges of Nursing [AACN], 2006; Hawkins & Nezat, 2009). This 
degree adds a combination of health policy and healthcare economics knowledge, organizational 
leadership and management expertise, inter-professional collaboration skills, and quality 
improvement and systems change process abilities.  The AACN (2006) recommends requiring 
this degree for new CRNAs by 2015, while the AANA (2007) supports 2025 as the deadline. 
The environment and culture of CRNAs. 
The ability of CRNAs to adequately manage pain is dependent in part on the environment 
in which they work.  This environment presents itself as a complex practice setting due to 
various interactions that occur between CRNAs themselves, patients, physicians, and other staff.  
Moreover, the decisions made to alleviate pain are not determined by a single consideration, and 
often occur in a multidisciplinary approach.   
CRNAs’ role in pain management. 
From training and experience, CRNAs possess the knowledge, skills, and techniques to 
deliver therapeutic pharmacological intervention in the management of both acute and chronic 
pain.  CRNAs are critical personnel in providing adequate treatment to alleviate pain in 
collaboration with other members of a multidisciplinary team (Stomberg, Sjostrom & Haljamae, 
2003).  The CRNA’s understanding of opioid tolerance is necessary for optimal pain 
management, as they are often the in-room providers for perioperative pain management.  The 
AANA (2010) has published a scope and standards document for nurses' anesthesia practice 
consisting of eleven standards, three of which are particularly relevant to opioid tolerant patients 




and thus this thesis.  The first AANA standard calls for accurate pre-anesthesia assessment—this 
is essential for understanding patients' history of opioid usage.  The third standard requires 
CRNAs to formulate patient-specific anesthesia plans—for the opioid tolerant patient, this 
requires incorporating the patient’s opioid history and calculating doses according.  Finally, the 
eleventh standard requires that the human rights of all patients be respected, which is important 
to remember since opioid tolerant patients may include those addicted to illegal drugs and 
commonly seen as undesirable members of society. 
Advocacy and ethics. 
In general, advocacy refers to extending unconditional support to the well being of the 
patient (Benner, 1999).  Advocacy is a fundamental aspect of the nursing profession and is often 
discussed in nursing literature (American Nurses Association, 2001; Courtenay & Carey, 2008; 
Gadow, 1980; Vaartio & Leino-Kilpi, 2005).  All ethical codes for CRNAs recommend 
advocacy as a core responsibility.  In all they do, CRNAs must be patient advocates—this 
morality drives every action a CRNA takes.  Advocacy requires extending active support to 
patients’ rights and choices, helping patients by clarifying medical decisions, and facilitating the 
interests of patients, all while providing autonomy and honoring privacy (Hamric, 2000).  As the 
focus on advocacy indicates, close attention to ethics is fundamental for CRNA delivery of high 
quality anesthesia.   
Challenges. 
Tolerance as a CRNA challenge. 
Tolerance to opioids naturally develops in most opioid users, whether chronic pain 
patients or illicit consumers, after long-term use.  The illicit user is often addicted, while the 
great majority of licit users are not (Manchikanti, Cash, Damron, Manchukonda, Pampti, & 




McManus, 2006).  However, in each case they are opioid tolerant thereby making management 
of their pain complex and challenging.  This thesis focuses on opioid tolerant patients regardless 
of the nature of the use and irrespective of the presence or absence of addiction.  Understanding 
the differences between tolerance, dependence, and addiction is important.  Basically tolerance is 
a physiological adaptation requiring more opioids for the same effect (and, implicitly, delivering 
a lesser effect—thus, inadequate analgesia—for the same dosage) (Mitra & Sinatra, 2004).  
Dependence is commonly understood as a physical state in which suspension of opioid 
consumption results in withdrawal symptoms, while addiction is a psychological condition 
involving drug craving and potentially abuse (Mehta & Langford, 2006, pp. 269-270; Morgan & 
Christie, 2011, p. 1322).  There is overlap between the three concepts, but they are importantly 
distinct. 
Rapp, Ready, and Nessly (1995) and more recently Patanwala, Jarzyna, Miller, and 
Erstad (2008) quantify what opioid tolerance implies for pain management.  Rapp et al (1995), in 
a case-controlled case review of 360 patients, reported a mean of 3 times the consumption 
(morphine equivalent) of patient-controlled anesthesia (PCA) within 24 hours after surgery (p. 
198).   Patanwala et al. (2008) in their prospective, observational study of 29 total knee 
arthroplasty patients, found a PCA multiple of 7.  In both studies the patients with a history of 
opioid use also had significantly higher pain scores despite the increased PCA, possibly 
indicating hyperalgesia.  While these multiples cannot be generalized to dissimilar cases 
and only a thorough patient history can suggest the optimal dosing in any particular case, these 
studies do empirically confirm that a prior history of opioid use will dramatically increase opioid 
requirements. 
Mechanisms of tolerance. 




Generally, upon initial administration of opioids, analgesia occurs but may be 
accompanied by sedation, vomiting, nausea, pupillary constriction, euphoria, or dysphoria.  After 
repeated administration, the body begins to selectively develop tolerance for these different 
effects at different rates (Collett, 1998).  For example, tolerance to nausea occurs rapidly while 
tolerance to constipation occurs relatively slowly, if at all.  Different opioid agonist through 
receptor desensitization cause opioid tolerance (Bailey et al., 2009). 
Opioids have a long history as analgesics, continuing to this day, almost alone being 
capable of relieving the extreme pain in a perioperative setting (Morgan & Christie, 2011).  
There are many opioid drugs available, some of which are derived from the opium poppy (the 
opiates, e.g., morphine and codeine) and some synthetic (e.g., fentanyl and sufentanil).  They 
operate on the various opioid receptors of the central nervous system including the mu, delta, and 
kappa receptors.  These receptors consist of seven transmembrane domains that interact with G 
proteins to transmit signals downstream of the opioid agonist binding (Laugwitz, Offermanns, 
Spicher &Schultz, 1993).  The resultant signals cause analgesia and other effects of opioid 
binding including respiratory depression and euphoria (Traynor, 2012).  It is common knowledge 
that an overdose of opioids will result in increased side effects with no analgesic benefit, while 
too small a dose will result in undermanaged pain.  
Because the analgesic effect is caused by the binding of chemical receptors (primarily the 
mu receptor), the dose response curve assumes a steep sigmoid shape.  This is a common 
response curve for many drugs and is depicted in Figure 1. 
Running head: OPIOID TOLERANT 
 
 
Figure 1.  Dose versus analgesic response to opioid medication.
 
The graph illustrates a useful opioid dose response model based on the Fermi equation for the 
opioid dose-response curve (Peleg, Normand, & Damrau, 1997).  (
adopted in generating both the tolerance graph and the tolerance
represents the single-dose response to an opioid.  The response 
patient and, although difficult to 
patient at optimal dosing.  Noteworthy is the narrow dose window caused by the steepness of the 
response curve:  too-low doses are almost completely ineffective, and doses above the ideal 
provide little or no benefit (since the receptors are already saturated)
effects. The phenomenon of tolerance may be pharmacologically modeled by a family of curves, 
requiring larger doses (that is, the curves shifting to the right) as tolerance increases (
Figure 3 illustrates the tolerance effect of requiring larger doses while having less pain relief 
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Figure 2. The dose needed for a given response increases with tolerance. 
 
 
Figure 3. Hyperalgesia shifts the curve similarly to tolerance but also, by increasing pain 
sensitivity, implicitly reduces the maximum opioid analgesic response, sometimes 
resulting in the failure of opioid analgesia to control all pain, practically requiring a 
multimodal response. 
 
In describing these effects physiologically it is important to note, as Farquhar-Smith 
(2007, p. 3) explained, that  
Nociceptive energy is transduced into electrophysiological signals that are 









































“hard wired”, but undergoes profound functional changes and modulation 
under certain conditions, such as tissue damage and inflammation (e.g., 
postoperative pain).  
Opioid-induced tolerance and hyperalgesia are pharmacodynamic examples of pain pathway 
modifications (Farquhar-Smith, 2007). 
Opioid hyperalgesia. 
 Another complicating factor caused by changes in opioid receptors is hyperalgesia.  
High-dose opioid regimens may cause a paradoxical increase in pain sensitivity.  This requires 
higher doses for relief, ironically resulting in more hyperalgesia, requiring still more opioids for 
relief—an upward spiral of dose escalation.  It may be necessary to reduce or even eliminate the 
opioid to reverse hyperalgesia (Silverman, 2009, p. 680).  Pain may be poorly controlled during 
this process, despite large opioid doses, creating difficulties (barriers) for CRNAs managing 
these patients. 
 One way to circumvent the further progression of opioid tolerance is to engage different 
receptors and nerve pathways, such as multi-modal drug treatment and adjuvants which can 
reduce opioid use and thus their side effects as proposed by DuPen, Shen, and Ersek (2007) in 
their comprehensive review of tolerance and hyperalgesia mechanisms. 
Pain guidelines. 
The most relevant guidelines for perioperative pain management of opioid tolerant 
patients come from the American Society of Anesthesiologists (ASA), yet, neither practice 
guideline, acute (2004) nor chronic (2010), focuses on the opioid tolerant patient in a 
perioperative context.  While the chronic guidelines implicitly deal with a partially opioid-
tolerant population (since many chronic pain suffers are prescribed opioids and many others rely 




on NSAIDs or acetaminophen), the opioid tolerant patient and chronic pain suffering populations 
only partially overlap, so guidelines for chronic pain sufferers cannot presumptively be taken as 
guidelines for the opioid tolerant. 
Purpose of the Study 
The main goal of this study was to provide an accurate description of the perception of 
pain management practices among CRNAs and to understand various barriers that prevent the 
delivery of appropriate pain management to opioid tolerant patients.  This systems change 
project creates a foundation for both practical changes and future research. 
The project objective was to answer the following questions: 
1. How do CRNAs manage patients with a history of opioid tolerance presenting for 
surgery? 
2. What do CRNAs identify as barriers when managing the opioid tolerant patient? 
Limitations of the Study 
1. The study is limited to CRNAs practicing in the United States and therefore it cannot 
be generalized to all CRNAs. 
2. This is a descriptive study; inferential analysis was not conducted. 
3. The highly subjective nature of the survey and the questionnaire. 
4. Day to day variations that are beyond the control of the researcher. 
5. Participant bias due the pressure of the obligation to respond in a socially acceptable 
manner. 





1. That the participants responded honestly and to the best of their knowledge to the 
study survey. 
2. That the responses on the survey instrument accurately reflect the CRNA 
respondents’ practices of pain management for opioid tolerant patients. 
3. That the CRNAs completing the questionnaire will have thorough understanding of 
the questions being asked and also have previous experience with the phenomenon of 
interest. 
Timeframe 
This project was conducted from October 2010 through December 2011. 
Definitions of Terms 
1. CRNA: a Certified Registered Nurse Anesthetist, that is, an advanced practice registered 
nurse specializing in anesthesia.  
2. Pain Management: provision of care that reduces or eliminates pain in patients in 
perioperative settings  
3. Opioids: a group of chemical substances that cause morphine-like stimulation in the body.  
Opioids function by binding to opioid receptors, resulting in activation of a series of neuro-
chemical pathways.  Opioid receptors are distributed widely in the neuronal system.  
Opioids can be classified into natural opioids, morphine derivatives semi-synthetic opioids, 
fully synthetic opioids, and endogenous opioids (Barash, 1993).  
4. Opioid-Induced Hyperalgesia: a clinical condition under which increase in pain occurs in 
patients after receiving repeated doses of opioids. This requires higher doses for relief, 




ironically resulting in more hyperalgesia, requiring still more for relief—an upward spiral of 
pain and dose escalation. 
5. Tolerance: an adaptation state wherein drug exposure results in a decrease in the effect of 
the drug as a function of time and dose. Tolerance in isolation is not necessarily a sign of 
addiction (Mitra & Sinatra, 2004). 
6. Addiction: a maladaptive state in which a person craves and has impaired control over 
compulsive drug use, despite harmful results (Collett, 1998). 
7. Multimodal analgesia: an approach during pain management that combines various drugs 
(opioid and non-opioid analgesics, local anesthetics) and delivery techniques (e.g. 
intravenous anesthesia, patient-controlled anesthesia, regional blockade, and epidural) and is 
currently identified as a best practice in pain management (Dahl & Raeder, 2000). 
8. Preemptive analgesia: analgesic treatment started before the induction of noxious stimuli.  
This approach reduces both the perioperative pain and reduces the frequency of post-
operative pain (Grape & Tramer, 2007).  
9. Post-Operative: perioperative but after the relevant surgery (i.e., excluding an extended time 
period). 
Summary 
This chapter provided a comprehensive background for this study of CRNAs’ self-
perceptions of pain management of opioid tolerant patients in order to identify major barriers 
pertaining to such.  Controlling pain in this group of patients is highly complex due to the 
analgesia-nullifying effects of tolerance (and sometimes concomitant hyperalgesia).  Due to the 
multiple concerns regarding side effects of opioid treatment (including respiratory depression, 
nausea, vomiting, and constipation), opioid-sparing modalities must play a major role in 




analgesia with opioid-tolerant patients.  Non-pharmacodynamic impediments include the lack of 
appropriate guidelines and the variations in the practice environment.  A literature review 
(following) supports the significance of this study, detailing some of the possible barriers to 
optimal care, raising questions which this study helps to answer empirically to the end of optimal 
pain relief for opioid tolerant patients. 
Forecast 
Chapter one provided an overview of the project.  The second chapter focuses on offering 
a theoretical framework based on Benner (1984, 2001) as it parallels the practice of the nurse 
anesthetist and the ethics of nursing, particularly as pertains to the responsibilities of CRNAs in 
pain management of opioid tolerant patients.  This chapter also includes a comprehensive 
literature review and notes the relevant scholarly works that help CRNAs understand pain 
processes, opioid tolerance, and opioid-induced hyperalgesia.  Chapter 3 explains the 
methodology used in this systems change project while Chapter 4 presents the results of this 
thesis’s survey of CRNAs from across the United States.  The final Chapter 5 puts the findings 
from the study in perspective, discussing conclusions and identifying recommendations for 
potential future studies. 
 
  




Chapter Two: Theoretical Framework and Literature Review 
The theoretical framework of this system change project was chosen with the assumption 
that there exists substantial and unnecessary pain perioperatively in the opioid tolerant patient, 
and expert CRNAs are required to address this important practice problem. The validity of this 
assumption is explored via the literature with a view to finding probable causes for this failure of 
the medical system.  These systems failures are commonly called “barriers” to adequate pain 
relief (Coker, Papaioannou, Kaasalainen, Dolovich, Turpie, & Taniguchi, 2010).  This study will 
focus upon these barriers to ideal analgesic practice which are under the control of the CRNA 
and may be practically addressed in the clinical setting. 
Underlying this work is another assumption: that there exists an optimal dose of opioids 
(combined with adjuvants and other opioid-sparing approaches) which balances pain relief and 
negative side effects, both of which are assumed to increase with concentration of opioids in the 
blood.  CRNAs estimate and administer these doses relying upon their skill and experience, 
which thus assume conceptual relevance to this thesis.  Barriers to the calculation and 
administration of this dose and succeeding doses are targeted for study via the questionnaire 
section of this study, which will provide data for the analysis of barriers and permit solutions to 
be deduced. 
Theoretical Framework 
The removal of barriers to good practice requires a growth process.  This process can be 
conceptualized as a development from lesser to greater competence.  As knowledge of barriers is 
internalized by the CRNA, a holistic view of the problem will develop through stages of growth 
(Jackson, Clements, Averill, & Zimbro, 2009) 
Benner (1984) has taught that nurses’ skills go through five distinct stages of 




development: (1) novice, (2) advanced beginner, (3) competent, (4) proficient, and ultimately 
(5) expert (1984).  As nurses’ experience and education increases, the ability to handle complex 
clinical situations (such as opioid tolerance) also increases.  These stages are significant enough 
to warrant additional detail. 
Novice.   
Since beginners lack experience, they must rely on scripted roles and rules to perform 
their duties.  Benner (1984, p. 23) noted:  
The rule-governed behavior typical of the novice is extremely limited and 
inflexible.  The heart of the difficulty lies in the fact that since novices have 
no experience of the situation they face, they must be given rules to guide 
their performance.  But following rules legislates against performance 
because the rules cannot tell them the most relevant tasks to perform in an 
actual situation.  
Advanced beginner.   
Those at the advanced beginner level of proficiency have some experience and can 
handle many real world situations.  Therefore, “[t]he advanced beginner or that person’s 
instructor can now formulate principles that dictate actions in terms of both attributes and 
aspects” (Benner, 1984, p. 23). 
Competent.   
Competent nurses in general have several years of practical experience.  They are 
characterized by the ability to formulate long range goals and the plans to achieve them.  Benner 




(1984) noted, “Hence, for the competent nurse, a plan establishes a perspective, and the plan is 
based on a considerable conscious, abstract, analytic contemplation of the problem” (p. 26). 
Proficient.   
As holistic perception develops, unconscious heuristics govern problem solving at this 
level of development.  Problem solving becomes less self-conscious and more self-evident. 
Benner provides the following analysis: “[c]haracteristically, the proficient performer perceives 
situations as wholes rather than in terms of aspects, and performance is guided by maxims” 
(Benner, 1984, p. 27). 
Expert.   
Expert performance transcends analysis and rule-following.  Problems and solutions are 
experienced as gestalts.  Benner (1984) stated that, “[e]xpert clinicians are not difficult to 
recognize because they frequently make clinical judgments or manage complex clinical 
situations in a truly remarkable way” (p. 34).  
Furthermore, Benner’s theory illuminates the process by which CRNAs undergo 
transformation of personal growth through experience and education.  Benner’s work spotlights 
the conceptual guideposts which mark the way along the path from novice to expert.  On one end 
of the spectrum is the novice, who lacks the experience in caring for the opioid tolerant patent.  
On the far end of the spectrum is the expert who is able to gestalt the situation and integrate 
scientific knowledge and experience to better serve the patient. 
Review of the Literature 
The literature review focuses broadly on three areas of content.  First is the primary 
causes of pain, classifying pain according to mechanisms of neural stimulation, elucidating 
normal pain pathways, and explaining how these pathways become dysfunctional in opioid 




tolerant patients. Second, current pain relief pharmacology is reviewed, including multimodal 
and preemptive analgesia as sophisticated means of managing pain particularly in relation to the 
opioid tolerant patient.  Finally, it highlights the barriers related to tolerance, hyperalgesia, and 
the medical-legal milieu.  
 The literature review was conducted using Internet search engines, including PubMed, 
CINAHL, EBSCO, Medline, and Google Scholar; academic reference lists and textbooks; and 
librarians, colleagues, and advisors who provided key input and greater research depth than 
would otherwise be possible. 
The nature of pain. 
Pain plays an essential role in human and animal survival: it protects the organism by 
discouraging harmful behavior.  Those people who have rare conditions making them incapable 
of feeling injury-related pain (e.g., those suffering from leprosy) often inflict grievous harm upon 
themselves unknowingly.  Pain acts upon the nervous system with high priority.  It gets our 
attention directly, not allowing us to slowly analyze the situation.  Analogous to a computer 
interrupt which stops all other action until it is handled, pain ensures that harmful events are 
promptly engaged.  Furthermore, painful lessons are remembered with intense emotion: “once 
bitten, twice shy.” 
But occasionally, pain is dysfunctional—most obviously perioperatively.  Pain often 
serves no purpose here because responsibility for the prevention of bodily harm then resides with 
the clinical staff, though even there, pain is sometimes a useful indicator for the clinician of 
previously unknown issues.  Preventing pain becomes an urgent and critically important but still 
routine clinical duty.  In this context, the idea that pain is somehow “good for you” is completely 
outmoded and anachronistic. 




Surgery without analgesia would be extraordinarily painful; this was the reality back in 
the days when a “Sawbones” surgeon’s skill was largely a function of the speed of amputation.  
With the advent of modern pharmacology, surgical pain could in theory be eliminated (Langford, 
2006).  Despite this, too often perioperative pain tenaciously persists (Brennan et al., 2007). 
Classification of pain. 
Pain may be classified based upon the mechanism of its generation or the duration of 
painful sensation.  The primary mechanisms of pain are nociceptive and neuropathic; the 
duration of pain is traditionally considered as acute (less than 3-6 months) or chronic (more) 
(Turk & Okifuji, 2010). 
Nociceptive pain is usually associated with a distinct cause.  In the surgical setting it is 
caused by the trauma of surgery and related disease.  The nociceptive fibers of the peripheral 
nervous system respond to damage and transmit signals interpreted as pain.  Nociceptive pain is 
further subdivided into somatic and visceral pain.  Somatic or body pain is usually sharp and 
localized; visceral pain occurs deeper in the body and is often dull and diffuse as reviewed by 
(Farquhar-Smith, 2007). 
Furthermore, Farquhar-Smith (2007) described another mechanism of pain is neuropathic 
pain. This type of pain is generally not associated with external stimuli, caused instead by 
malfunctioning pain neurons.  It may be considered a dysfunction of the pain pathways, serving 
no purpose for the sufferer.  Examples are diabetic neuropathy, cancer pain, or pain occurring 
after a stroke.  
Acute pain generally has a specific cause; chronic pain may continue long after the 
primary disease mechanism is resolved or may be due to the continuing progression of the 
disease.  As a disease progresses (e.g., a cancer metastasizes), pain and the need for relief may 




increase, usually requiring larger opioid doses.  “Progressive and prolonged stimulation of pain 
causes increased excitation of neurons in the dorsal horn of the spinal cord.  This phenomenon is 
sometimes referred to as ‘wind-up pain’” (Katz, 2002, p. 67). 
Pain of any classification is a matter of degree; yet as a subjective phenomenon, it is 
difficult to quantify precisely.  Unfortunately, “[t]he lack of quantifiable measures of pain 
character and intensity as well as relief negatively affects practice and research” (O'Malley, 
2005, p. 236).  Despite this, the CRNA needs to be able to estimate the patient’s pain in order to 
control it.  Various pain scales are used in the clinical setting with simplistic but helpful icons 
such as smiling or frowning faces.  These help the patient report the degree of pain and the 
clinician to titrate the analgesic dose to achieve optimal pain management.  
Pharmacology for pain. 
The modern array of drugs available to treat pain is effective and quite safe when handled 
with proper care and expertise.  Opioids are very effective analgesics, making them the mainstay 
in managing pain.  Newer opioids (e.g., fentanyl and hydromorphone) have further improved 
pain management (Inturrisi, 2002).  Some of the major concerns with opioid treatment include 
tolerance, addiction, and dependence.  Since opioids act by binding to opioid receptors, some 
preclinical studies have used simultaneous receptor engagement modalities in order to minimize 
these (Morgan & Christie, 2011).  Careful calculation of the minimum effective opioid dose is 
necessary. 
Optimal opioid dose calculation. 
Calculating the proper dose is complex (Mehta & Langford, 2006).  There is often a 
maintenance component to the baseline dose which must be converted to common units and 
added to the total dose.  This is ideally done via an opioid calculator which converts the patient’s 




maintenance opioid dose to a morphine-equivalent and then to the opioid used perioperatively 
(Pereira, Lawlor, Vigano, Dorgan, & Bruera, 2001). 
Despite the precision and convenience of an opioid calculator, most practitioners simply 
rely upon experience when determining doses (Plagge, Ruppen, Ott, Fabbro, Bornand, & 
Deuster, 2011), which is fine in principle, but could be a source of errors.  Errors are typically 
corrected in subsequent doses by a feedback process (Plagge et al., 2011), continually increasing 
the dose according to the patient’s pain response until (ideally minimum) sufficient dosing is 
realized, or decreasing it if side effects become excessive (e.g., respiratory depression).  Initial 
patient pain is a byproduct of initial suboptimal dosing since the titration process takes time. 
Davis, Johnson, Egan,Vezina, Snell, and Swenson (2003) presented a case report 
detailing how they experimentally determined the perioperative response of an opioid tolerant 
patient to fentanyl.  Feedback from the patient recorded as vital signs were used to titrate the 
proper dose, which was extremely high.  Davis et al. (2003, p. 1662) pointed out: 
Our target fentanyl effect-site concentration of 73 ng/ml was 50-70 times 
larger than the concentration usually associated with analgesia in opioid 
naïve patients.  It is extremely unlikely that such an aggressive infusion rate 
would have been attempted in the absence of information gained during her 
initial response to a large-dose fentanyl infusion.   
This illustrates the tremendous increase in opioids that some patients need.  As Davis and 
colleagues perspicaciously concluded, these patients are not likely to receive their optimal dose 
without extra effort on the part of the pain team.  Using an opioid calculator minimizes the need 
for titration and the resulting pain and side effects; yet, even the most careful patient history and 
opioid calculation may be overridden by the patient’s actual response to the planned analgesia. 




Emergence of effective opioid calculation methods to convert oral morphine to IV dose would 
help alleviate these problems (Patanwala, Duby, Waters, & Erstad, 2007). 
Preemptive analgesia. 
The postoperative patient is extremely vulnerable and may have experienced significant 
surgical trauma.  Preoperative opioid dose calculations, which take into consideration 
maintenance dose consumption, can help prevent post-operative pain, as can judicious use of 
adjuvant medication (Katz, 2002).  The effects of preoperatively administering non-opioids may 
also be beneficial, sometimes reducing perioperative opioid requirements by 20-35% and 
increasing the duration of pain relief (American Society of Anesthesiologists, 2004).  
Multimodal analgesia. 
Multimodal analgesia is the clinical practice of combining opioids with other drugs and 
techniques to achieve additive or synergistic effects.  Various opioids may also be used, since 
each has a somewhat different pharmacological profile and attendant side effects.  Additionally, 
different routes may be chosen for delivery including oral, parenteral, subcutaneous, and 
intravenous. 
The major drug categories used in multimodal analgesia comprise local anesthetics, non-
steroidal anti-inflammatory drugs (NSAIDs), alpha2-adrenergic agonists, cyclooxygenase-2 
(COX-2) inhibitors, NMDA antagonists, and opioids (Katz, 2002).  This multimodal approach 
demonstrably spares opioids, thereby sparing the patient the adverse effects of opioids (Barash, 
Cullen, Stoelting, Calalan, & Stock, 2009; Dahl & Raeder, 2000; Kehlet & Wilmore, 2002; 
Shang & Gan, 2003; Walker, Goudas, Cousins, & Carr, 2002). Unfortunately, the multimodal 
approach is not a panacea because each of these drugs has its own side effect profile which limits 
utility in some patients (Katz, 2002).  





 Local anesthetics work by blocking pain impulses at the site of injury or of nerve 
conduction.  Used extensively (but judiciously) in surgery, local anesthetics may allow both the 
sparing of opioids post-surgically and superior pain relief.  Long-acting versions are available for 
this purpose (Shang & Gan, 2003).  These drugs inhibit nociception by blocking nerve impulses 
at some point (e.g., the spine or neural plexus) between the traumatized site and the brain. There 
is a limit to the utility of local anesthetics as adjuvants due to side effects which include central 
nervous system effects (Buckley, 2000). 
Non-steroidal anti-inflammatory drugs (NSAIDs). 
 NSAIDs are very common adjunct medications in surgical anesthesia.  They exhibit 
opioid-sparing properties which can substantially reduce opioid requirements.  The combination 
may also achieve improved analgesic effectiveness over opioids alone. NSAIDs generally inhibit 
inflammation by inhibiting the arachidonic acid pathway.  This inhibits inflammation mediators 
such as the prostaglandins.  Of particular importance, cyclooxygenase-2 (COX-2) enzymes are 
involved in the pathway (Moiniche, Kehlet, & Dahl, 2002).  NSAIDs inhibit COX-2 activity thus 
preventing synthesis of prostaglandins.  COX-1 enzymes may also be inhibited leading to 
hemodynamic and gastrointestinal effects (White 2005).  The mechanism of inhibition of COX-2 
varies among NSAIDs giving each of them a unique pharmacological profile.  They may be of 
long duration and preoperative administration can decrease postoperative pain and thus spare 
opioids (Sinatra, 2002). Side effects are common, including gastrointestinal disturbances and 
increased bleeding from anticoagulation effects (Souter, Fredman, & White, 1994). 
 




Cyclooxygenase-2 (COX-2) selective inhibitors. 
 Older NSAIDs inhibit both COX-1 and COX-2; selective COX-2 inhibitors such as 
celecoxib are specific to the COX-2 enzyme, leading to reduced side effects such as bleeding and 
gastrointestinal problems.  COX-2 inhibitors may be used preemptively by preoperative 
administration to help counteract postoperative pain.  Opioid doses may thus be reduced while 
pain relief is enhanced (Katz, 2002). 
Gabapentin.  
 Gabapentin is an anti-epileptic drug that has proved useful as an adjunct to opioid 
medication.  Most researchers agree that preoperative gabapentin reduces opioid requirements; it 
may also improve postoperative pain scores (Eckhardt, Ammon, Hofmann, Riebe, Gugeler, & 
Mikus, 2000).  Gabapentin also displays a strong anti-hyperalgesic effect, enabling the clinician 
to treat hyperalgesic pain and simultaneously reduce the amount of opioids (Buvanendran & 
Kroin, 2007; Buvanendran, Kroin, Della Valle, Kari, Moric, & Tuman, 2010; Mao & Chen, 
2000). 
Dexmedetomidine. 
 Dexmedetomidine is a relatively new opioid-sparing adjunct (White, 2005).  It is a highly 
selective centrally acting alpha2 adrenergic agonist (White, 2005).  It also minimizes muscle 
rigidity and respiratory depression (Arain, Ruehlow, Uhrich, & Ebert, 2004). 
 In a randomized, controlled, double-blind study conducted by Lin et al. (2009), 
dexmedetomidine was used in combination with morphine (versus morphine alone) in 50 out of 
100 patients who received PCA after undergoing total hysterectomies.  These patients used 29% 
less morphine even while reporting less pain, and the incidence of nausea and over-sedation was 




lower, demonstrating the opioid sparing and side-effect reducing properties of dexmedetomidine 
when used in conjunction with morphine.  
Ketamine. 
 Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist.  It is commonly used 
in clinical practice and in perioperative pain control (Kissin, 2005).  Ketamine may be used at 
sub-anesthetic doses to spare opioids and provide better analgesia (Himmelseher & Durieux, 
2005; Koppert & Schmelz, 2007).  Angst and Clark (2010, p. 514) noted, “A large body of work 
in laboratory animals indicates that ketamine can block the development of opioid tolerance and 
opioid-induced hyperalgesia and reverse both phenomena, at least partly, when already present.”  
Ketamine is useful in preventing opioid-induced hyperalgesia in patients receiving chronic high 
doses of opioids (Gottschalk & Smith, 2001; Kehlet & Dahl, 1993; Kissin, 2005). 
Droperidol. 
Droperidol may be used as an opioid adjuvant (Richards, Richards, Ozery, & Derlet, 
2011). It is similar to haloperidol and does not cause respiratory depression, though it may cause 
amnesia.   
Barriers to optimal pain management. 
 There exist many potential barriers to optimal clinical practice (Glajchen, 2001).  
Removal of these barriers may be effected by system changes, educational advancement, and 
personal growth, as well as attitude changes (Gunnarsdottir, Donovan & Ward, 2003). 
For the purpose of this study, “barriers” are any personal or system problems that cause 
suboptimal treatment of the opioid tolerant patient.  Barriers for pain management of patients 
generally may include ignorance, fear, negative attitudes, communication problems, a rushed 
workplace, legal concerns, cultural bias, fear of addiction or respiratory depression, patient fears, 




lack of calculation skills or assessment ability, among others (Murnion, Gnjidic, & Hilmer, 
2010).  
A nursing study shed light on this as well.  Bourne (2008) studied the current practice in 
London hospitals of opioid tolerant pain management.  Her results revealed that none of the 10 
hospitals had a protocol in place for cancer patients who are opioid dependent even though 9 out 
of 10 have a regular practice including opioid tolerant patients.  Similarly, none of the hospitals 
used the same method of PCA for patients who were on opioids preoperatively.  Thus, high 
variability was observed among hospitals when treating pain in opioid tolerant patients. 
Management of perioperative pain in the patient with prior use of opioids requires a deeper 
understanding of the patient and their pain experience, and it is essential to think in advance 
about the patient’s post-operative response to acute and chronic pain.  The demonstrated lack of 
consistency does not prove a problem—ideally, it could be the result simply of individualizing 
care appropriately—but it does raise questions as to whether there should be more of a “best 
practices” approach via improved guidelines, and whether effort is needed to make the opioid 
tolerant pain care less an art and more a science (Bourne, 2008). 
Medical legal scrutiny.   
 Legal and other system barriers may contribute significantly to the under-treatment of 
pain.  O’Malley (2005) made the point that “[a]nother hidden force supporting the under 
treatment of pain are [sic] the fears of regulatory scrutiny in prescribing opioids, which translates 
into tolerance for poor care” (p. 236).  Opioids generally are controlled substances in the US (and 
most countries) where there are six schedules of ever-greater control depending upon their abuse 
potential and medical utility (Dews & Mekhail, 2004).  Federal laws are designed to prevent 
abuse and diversion of drugs while permitting legitimate medical use (Gilson & Joranson, 2002).  




State regulations, which may be more restrictive than federal laws, often play a major role in 
controlling the medical practices of clinicians.  That it is safer from a legal perspective to under-
prescribe opioids may effect a non-medical administrative or psychological barrier to optimal 
pain relief (Gilson & Joranson, 2002), leading to poor pain management in some patients 
(O'Malley, 2005). 
Summary 
 This section discussed the theoretical framework behind this study by describing 
Benner’s theory of novice to expert practice and identifying barriers to pain management and the 
importance of removing such barriers for effective pain management, particularly from an expert 
CRNA practice perspective.  The review of literature identified aspects of pain including its 
classification, mediators, mechanisms of origin, analgesics, and the resistance mechanisms to 
effective opioid treatment, such as hyperalgesia and tolerance.  Finally, emphasis was also placed 
on the need for developing optimal opioid dose calculations, the role of preemptive analgesia and 
multimodal analgesia, and the use of adjuvants during pain management.  The literature on 
barriers to optimal treatment of opioid tolerant patients was also reviewed.  The methodology of 
the study will follow in Chapter 3. 
 
  




Chapter 3: Methodology 
The purpose of this study is to gain and promulgate insights into barriers in optimal 
CRNA pain management of opioid tolerant patients so as to help remove such barriers, via 
surveying CRNAs regarding their self-perceptions of the matter.  This chapter addresses the 
research design, instrumentation, sampling, ethics, and data collection as they are relevant to this 
project. 
Research Design 
The study uses a descriptive online survey that was distributed to a random sample of 
CRNAs provided by the American Association of Nurse Anesthetist (AANA).  Subjects were 
allowed a fourteen day period to complete the survey, and were advised that completion would 
take less than three minutes.  All respondents completed a multiple-choice questionnaire 
assessing their self-perceptions of management of opioid-tolerant patients, e.g., their attitudes 
towards current modalities and protocols for dealing with these, and the barriers commonly 
encountered when caring for this population (See Appendix A). 
Methodological Rationale 
The goals of a descriptive study are to observe, describe, and document aspects of a 
reality in situ, as it occurs naturally (Polit & Beck, 2011).  A questionnaire was created for this 
study as it represents a standardized, cost-effective, and anonymous instrument that is capable of 
reaching a large and geographically dispersed sample (Frazer & Lawley, 2000; Polit & Beck, 
2011).  The questionnaire was structured in accord with professional relevance so that the most 
useful questions were placed at the beginning, the most sensitive and emotionally charged in the 
middle, and those pertaining to demographics at the end (Frazer & Lawley, 2000). 




Ethics and Protection of the Human Rights of Participants 
Prior to the study’s initiation, approval was obtained from the Institutional Review Board 
of St. Catherine University.  In keeping with the board’s requirements, each potential respondent 
was provided with an invitation informing them that participation in the study was completely 
voluntary and that there was no practical risk in participating (See Appendix B).  Respondents 
were assured that all results would be handled anonymously, that no personal identifiers could be 
connected to completed surveys, and that the choice to respond to the invitation and participate 
in the survey confirmed informed consent. 
Sample 
The sample used for this study was drawn from the AANA’s 2010 registry of CRNAs.  
The AANA was selected as a source because the vast majority of all CRNAs in the United States 
are members of the organization and practice in many setting including urban, 
university/teaching and rural hospitals.  The source population included all such currently-
practicing CRNAs who have either been certified or re-certified.  More than 29,000 AANA 
members met the selection criteria, and 2,500 were randomly selected for participation in the 
study.  These 2,500 were e-mailed an invitation to participate, an explanation of the survey, and a 
link to the survey itself.  The response rate on individual questions ranged from 25.6% (640 
respondents) to 28.9% (717), the response rate generally declining marginally with each 
question. 
Data Collection 
Data for this study were collected using a controlled-access web-based multiple choice 
questionnaire designed by the investigator in consultation with three Masters-certified CRNA 
educators and one board-certified anesthesiologist, all specializing in pain management and 




research, and a professional survey analyst.  The instrument was first tested using a small pilot 
study of ten randomly selected CRNAs so as to confirm the questions’ validity.  Thus this 
questionnaire was sent to 10 randomly practicing CRNAs across the United States. The feedback 
from these CRNAs includes: ease of understanding the material, relevance of the material to 
their practice, clarity of the material, and the time consumed to finish the questionnaire. It made 
use of the Likert frequency scale, which is regularly used in research to measure attitudes or 
opinions because its ordinal nature allows respondents to express a full range of views in their 
responses  (Matutina, Newman, & Jenkins, 2010; Polit & Beck, 2011). 
Aside from asking basic demographic questions, the survey consists of three overarching 
groups of questions: eight questions regarding self-perceptions (e.g., attitudes towards opioid-
tolerant patients, assessment practices, and knowledge of pain modalities); two questions related 
to education and CEUs; and four questions regarding extant barriers inhibiting provision of 
optimal pain relief (See Appendix A).  All of the questions were in line with the research 
question and focused on analgesia for the opioid-tolerant patient population.  
Data Analysis 
All data obtained were analyzed through standard methods for each of the survey’s 
questions.  This analysis provided the foundation for the study’s insights regarding pain 
management practices for CRNAs dealing with opioid-tolerant populations.  Findings are 
presented in Chapter 4. 
  




Chapter 4: Results 
CRNAs along with anesthesiologists are entrusted with the duty of alleviating pain.  
Adding complexity to an already complicated process is opioid tolerance.  This study was 
designed to identify and understand barriers that potentially impede delivery of adequate pain 
management to opioid tolerant patients.  As the primary instrument of the study, a questionnaire 
was designed and submitted to 2500 CRNAs throughout the United States, whose names are in 
the AANA database; of those surveyed, 28.9% (717) responded, a minimum of 25.6% (640) on 
each question.  Missing or invalid responses were omitted from particular results, the n value on 
each survey question’s chart showing the quantity of respondents to that question. 
Demographics 
Educationally (Figure 4), over three-fourths (78.5%) of the participants have a master’s 
of nurse anesthesia equivalent or higher degree, 89.3% are working full time (Figure 5), and 
92.9% work in hospitals (Figure 6).  The clinical practice settings of participants (Figure 7) were 
as follows: in rural/small town (27.1%), university/teaching (33.6%), suburban (27.9%), or 
urban/community (11.5%).  The median age (Figure 8) was 50 years (IQR=16, range 29 to 78 
years), with a mean years of CRNA experience of 16.0 years (SD+/-10.9, range 1.5 to 55 years) 
(Figure 9). 
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Figure 4. Survey question: what is your highest level of education as a CRNA? 
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Figure 6. Survey Question: what best describes your practice?
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Figure 8. Survey question: what is your age?
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The following provides a descriptive analysis of various factors that contribute directly 
during the delivery of appropriate pain managemen
CRNA Assessment and Frequency of Opioid Tolerant Patients
Not surprisingly, almost all of the CRNAs provide personal 
assessment of patients (91.3%); it may be a concern that some report they do not (8.7%) 
10).  As depicted in Figure 11, 66.0%
to be opioid tolerant, while 22.6% (146) report 21 to 40%
range of 61-100%.  Taken together, all but 
conducted pain management of patients who are opioid tolerant.





Do You Personally Assess Your Patients for Their History of Opioid Use or 
 
 
t therapy to opioid tolerant patients.
 
opioid use or tolerance 
 (426) of CRNAs reported that up to 20% of 
; less than 3% of CRNAs report 
4 (<1%) of the CRNA participants in this study have 
 
ory of opioid use or 












Running head: OPIOID TOLERANT 
 
 
Figure 11. Survey question: about what percentage of your patients are opioid tolerant?
Nature of CRNA Practice 
While managing pain in opioid tolerant patients, it is beneficial that the place of 
employment has the infrastructure to support acute pain management follow
CRNAs involved in this study report 
management services at their place of employment; 11% are unsure.  Half of the CRNA 
participants in this study work collaboratively with physicians 
independently.  Among the CRNAs who have a collaborative practice (327), three
equipped with the power of making 
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Figure 12. Survey question: does your primary place of employment have inpatient acute pain 
management services to follow-up on pain management of opioid tolerant patients?
 
Figure 13. Survey question: do you have a collaborative practice in pain management with an 
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Figure 14. Survey question: if you work in a collaborative practice in your primary place of employment, 
are you the one to make decisions as to the
Pain Management Practices of CRNAs 
Proper dosing is essential for adequate pain management.  In this regard
of respondents were always and 71% usually confident in their dosing of opioid tolerant patients. 
It is a matter of concern that 17% of CRNAs expressed only occasional confidence, 5% had 
confidence only rarely, and under 1% none at all, though it could be that in those cases doses are 
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Figure 15. Survey question: do you feel confident in determinin
patients?   
An opioid calculator assists
majority of the CRNAs in this study
do (Figure 16).  Four-fifths (79%
management modalities for opioid tolerant patients (
adjuvant medications with opioid tolerant patients an average of 68% of the time (
and 91% of CRNAs employ multi
such patients (Figure 19). 
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Figure 16. Survey question: for your opioid tolerant patients, is an opioid calculator used to determine the 
baseline dose?  
 
Figure 17. Survey question: how often
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Figure 18. Survey question: in approximately what percentage (0
include adjuvant pain medication?   
 
Figure 19. Survey question: how often for opioid tolerant patients do you use multimodal pain regimens 
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Barriers to Adequate Pain Management in Opioid Tolerant Patients
A disadvantage in using opioids 
3.9% of CRNAs agree (3.3% agree, 0.6% strongly agree) that this is a barrier 
management for in-hospital, perioperative use
Figure 20. Survey question: in your practice, is the fear of making patients (more) 
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In this study, 30.0% of CRNAs reported fear of induction of respiratory depression as a
optimal pain management, while 18
Figure 21. Survey question: in your practice, is the fear of causing respiratory depression a barrier to 
optimal pain management for opioid tolerant patients?
Another potential barrier might include a lack of CRNA autonomy, but only 25% of 
CRNAs reported this; most CRNAs (54% overall, 19% strongly) expressly denied this as a 
barrier (Figure 22). 
Figure 22. Survey question: in your practice, is your lacking autonomy in determining perioperative pain 
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.6% were neutral and 51.3% disagreed (Figure 
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The most widely and strongly agreed upon barrier is a lack of formal, profession
pain management guidelines specifically dealing with opioid tolerant patients.  Fifty percent 
agreed and 22% disagreed that envisaging specific pain guidelines would eliminate a barrier in 
pain management in these patients
Figure 23. Survey question: in your practice, is a lack of certified, professional guidelines
opioid tolerant patients a barrier to their optimal pain management?
Nearly all CRNAs (90%) do not consider 
management process (26% neither agree nor disagree, 46% disagree, 18% strongly disagree); 
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Figure 24). 
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Figure 24. Survey question: in your practice, is fear of litigation related to poor pain relief in opioid 
tolerant patients a barrier to their optimal pain management?
Figure 25. Survey question: are there any other barriers you encounter in managing the pain of opioid 
tolerant patients?   
In one open-ended question, respondents 
impede practice Figure 25).  Three
implicitly indicated there were no other significant barriers.  However, one
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Table 1.  Additional barriers 
Staff Issues 23 
Patient Prevarication 11 
Bleeding Increase 11 
Lack of guidelines 10 
Lack of knowledge 7 
Problems with multimodal 7 
Rushed work conditions 6 
 
Table 1 categorically summarizes most of (75) the 138 typed responses.  Responses not 
summarized here included more idiosyncratic (e.g., hospital-specific) or broad (e.g., “too many”) 
concerns and did not seem to be part of broader patterns.  Written responses related to barriers to 
practice were analyzed and categorized to determine that the largest groups of write-ins were: 
staff cooperation issues (23), patient prevarication (11), bleeding increases (11), lack of 
guidelines (10) (even though this was a specific question earlier in the survey), lack of 
knowledge (7), problems with multimodal anesthesia (7), and rushed work conditions (6). 
Continuing education provides an opportunity to accommodate recent advancements in 
drug discovery and therapy.  Almost 4/5 of the CRNA participants (78%) in this study had 
Continuing Education Units (CEUs) related to care of patients who are opioid tolerant within the 
past 2 years (Figure 26), and yet a striking 94% of the participants acknowledged the importance 
of having additional CEUs pertaining to opioid tolerant pain management (Figure 27). 
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Figure 26. Survey question: have you had any CEUs related to pain management for opioid tolerant 
patients?   
 
Figure 27. Survey question: how important to you personally 
management of opioid tolerant patients?
In summary, there is a need for professional guidelines for managing pain of opioid 
tolerant patients, and education toward that end.
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Chapter 5: Discussion 
The main objective of this study was to identify CRNA self-perceptions of pain 
management barriers when caring for opioid tolerant patients, and provide essential information 
to guide mitigating or eliminating those barriers, thereby reducing pain in this vulnerable 
population.  This is believed to be the first CRNA-oriented study of this kind. 
All CRNAs have a great responsibility to the patient because they are usually the in-room 
providers of pain relief in the intraoperative setting; this is magnified since nearly all but the 
most junior CRNAs should be experts in Benner’s use of the term (due not only to their 
advanced academic and clinical training but also, and in some ways even more importantly, to 
the certification’s requirements of prior nursing experience, implying that a “beginning” CRNA 
is already a proficient or expert nurse), and that expertise entails both greater authority and 
greater responsibility.  It follows that the training, attitudes, beliefs, and concerns of the CRNA 
will directly influence the care experienced by the patient, and that the self-perceptions of 
CRNAs provide insight into perioperative pain management and the associated barriers. 
This systems change project, then, taps the deep knowledge and wisdom of hundreds of 
practicing CRNAs representing a remarkable amount of clinical experience and insight.  
Referring to expert practitioners, Benner (1984) puts it well: “Their rich backlog of experience 
enables expert clinicians to create order in the midst of chaos” (p. 116). 
Findings 
CRNAs are registered nurses who possess at least a baccalaureate degree and one year of 
clinical experience prior to entering CRNA education; the majority of the participants in this 
study have earned a master’s degree.  The American Association of Colleges of Nursing (AACN, 
2006) recommends requiring a doctorate for entry to practice for all advanced practice nursing 




graduate programs by 2015; the AANA (2007) recommended mandating the DNP degree by 
2025.  Only 2.6% of the random sampling in this study had such a degree, but if these mandates 
become a requirement for certification, the percentage will increase dramatically in coming 
years.    
Successful perioperative pain management inevitably involves teamwork.  Most CRNAs 
execute their function under supervision (Jones & Fitspatrick, 2009) and collaborate with 
physicians, with the nature of this collaboration playing a critical role in the quality of care 
provided to patients (Taylor, 2009).  However, among the participants in this study, 49.1% do 
not have such a collaborative arrangement, implying that such CRNAs work alone and are 
therefore more autonomous.  It should also be noted that the majority of the collaborating 
CRNAs usually or always have freedom to choose the types and dosages of the analgesics that 
are to be administered to patients.  A recent report (Jordan, 2011) provided arguments that the 
removal of excess supervision is vital to ensure optimum patient access to care—this topic needs 
further systematic study.  This autonomy may be justified if the CRNA has climbed the expertise 
ladder as described by Benner (1984).  Among surveyed CRNAs generally, a quarter agree 
(5.3% strongly, 24.8% overall) that lack of CRNA autonomy in determining perioperative pain 
management is a significant barrier —whether this issue is a glass ¼ full or ¾ empty (20.9% 
neutral, 54.5% disagreeing) is difficult to discern, warranting further research. 
The pain management team ideally includes acute pain services.  Of CRNAs surveyed, 
42.0% reported having such services, 46.8% report lacking such services, and a disturbing 11.2% 
report that they do not know whether they have such services available or not.  The lack of 
awareness of available resources could in itself create a barrier to optimal pain management. 




Another putative barrier is the fear of inducing respiratory depression when administering 
opioids, seen by a significant but not overwhelming 30% of study participants as an actual 
barrier.  Respiratory depression is indeed a real risk, but opioid tolerant patients can receive far 
greater analgesic dosing before this becomes a problem (Thompson & Ray, 2003). 
Two other possible barriers to optimal pain management for opioid tolerant patients 
reassuringly proved to be statistically minor issues.  Fear of making the patient addicted (3.9% 
agree overall, 0.6% strongly; 96.1% neutral or disagreeing) is not a serious barrier in the view of 
CRNAs.  Addiction has proven to be a non-issue when using opioids precisely to manage pain 
(Compton & Athanasos, 2003), even over long periods, let alone perioperatively; so while the 
survey results are low, the evidence suggests they would ideally be zero.  Fear of pain-relief-
related litigation (10.5% agree overall, 1.4% strongly) is higher, but also quite rare, especially 
given medicine- and society-wide concerns about excessive litigation. 
The preceding important points being noted, by far the most dramatic results of this 
survey demonstrate the need and desire for additional precise CRNA guidance specifically 
concerning management of opioid tolerant patients.  The greatest barrier to optimal care reported 
in this study is an insufficiently detailed knowledge of just what care is needed.  Three elements 
establish this finding. 
Opioid calculator. 
First is the lack of use of an opioid calculator to determine precise morphine equivalents 
for opioid tolerant patients: 71.0% never and another 17.0% only rarely use an opioid calculator; 
just a miniscule 1.1% always do.  Individualizing pain management is generally critically 
important (Stomberg, Sjostrom & Haljamae, 2003), and particularly so for opioid tolerant 
patients.  Using intuition or experience to estimate a baseline is much better than ignoring opioid 




tolerance altogether, but may not be enough, particularly when simple and reliable opioid 
calculators are available (Agency Medical Directors’ Group, 2010).  Opioid calculators convert 
pre-operative oral opioid dosages into their IV morphine equivalents and back again (Patanwala, 
et al. 2007).  Excessive quantities of opioids can lead to respiratory depression, and inadequate 
levels do not alleviate pain. 
Professional guidelines. 
Second, one explicit barrier survey question had dramatically more agreement (50.0%) 
than disagreement (22.5% overall, 6.1% strongly) or neutrality (27.4%): the lack of formal 
professional guidelines for pain management of opioid tolerant patients.  Compared to survey 
results for other barriers noted above, this is decisive. This fits well, too, with the impressions 
gained from studies such as Bourne’s (2008) in which inconsistency of treatments and protocols 
for opioid tolerant patients was suggestive of inadequate guidance more than rigorous, patient-
centric treatment individuation.  Understanding the use opioids for treatment of chronic non-
cancerous pain (e.g., as reviewed by Ballantyne & Mao, 2003) could assist efforts to find proper 
perioperative procedures and dosing.   
Additional, targeted CEUs. 
Third, an exceptional 94% of participants believed they would benefit from more CEUs 
regarding handling opioid tolerant patients.  Interestingly, this 94% includes even the vast 
majority of those who did not agree that the lack of guidelines was a true barrier to optimal 
care—even without guidelines, additional education would be beneficial.  This is underscored by 
a recent study conducted by Leegaard, Watt-Watson, McGillion, Costello, Elgie-Watson, and 
Partridge (2011), which identified the need for nurse education as a key determinant toward 
achieving effective pain management in patients before and after surgery.  Some modes of 




education might include webinars or Internet AANA modules as well as the more traditional 
“brief in-services, hands-on learning, lunch-and-learn sessions, and designated education days” 
(pp. 318-319). 
Together, these findings suggest that targeted, evidence-based, precise guidance 
(ensuring use of an opioid calculator, creating professional guidelines, and additional CEUs) 
offers the best hope for improving pain relief for opioid tolerant patients.  Creating such state-of-
the-art guidance for managing these patients is a very challenging task, but this survey evidence 
indicates that it is the most important means to the end of better relieving their pain. 
 
Future Studies. 
Future research could use a numerical scale instead of a Likert scale when querying 
CRNAs about percentages of their anesthesia patients who are opioid tolerant.  Given the heavy 
preponderance of CRNAs who reported “1 to 20%” as their range (66%), a finer-grained 
breakdown would have been more appropriate.  Additionally, the issue of CRNA confidence 
relating to proper dosing of opioid tolerant patients may warrant additional investigation.  It is 
very important to consider also that higher confidence is not necessarily an indication of higher 
competence: in a situation where the CRNA has explicitly incomplete knowledge (e.g., about a 
patient’s opioid history), a more-expert CRNA may have less confidence in the precise dosing. 
Benner’s (1984) framework also offers opportunities for future research along these 
lines.  While unfortunately this study did not include the requisite background on pre-CRNA 
nursing experience, which would combine with years of experience as a CRNA to offer an 
overall time frame for statistically estimating a level of expertise, this lack does offer one clear 
path for additional questions and analyses.  Such research may require deriving a mathematical 




model from Benner's more intuitive philosophy, which derivation may be challenging but could 
offer informative correlation data allowing particular instantiations of Benner's philosophy to be 
tested. 
Benner, Expertise, and the DNP degree. 
Future research notwithstanding, looking at how these actual data fit with Benner’s 
theoretical framework is both illuminating and complicated.  As noted earlier, upon entering 
practice, most CRNAs by virtue of their education (both the criteria for admittance and the actual 
education itself) and experience (not only as CRNAs, but as nurses before their anesthesia 
training) may already be experts in Benner’s sense, but at the same time lack the most up-to-date 
expertise in managing the pain of opioid tolerant patients.  Core components of nurse anesthesia 
are fairly static and subject to accumulated individual experience, such as the basic science and 
the all-important human components; other aspects are subject to rapid change, such as the latest 
anesthesia empirical evaluations and technological breakthroughs.  Sound original training and 
years of experience suffice for the former, but not for the latter.  Use of the opioid calculator, the 
creation of new guidelines, and the acquisition of additional, targeted CEUs are all important 
supplements for core nursing and nurse anesthesia expertise.  Indeed, one way of understanding 
this systems change project is to see it entirely as a tool to ensure that CRNAs’ expertise, in 
Benner’s sense, includes the best practices for opioid tolerant patients. 
The DNP degree specifically facilitates the kind of expertise required to effect systems 
change.  The AACN (2006) determined eight essential characteristics of doctoral degree 
programs for Advanced Practice Registered Nurses (APRNs) to imbue DNPs with the 
capabilities to lead such change.  The IOM (2010) report on the future of nursing dovetails with 
this, encouraging registered nurses (RNs) and APRNs to pursue lifelong learning to maximize 




their professional training and thereby optimize healthcare outcomes for their patients, noting 
that getting the most from nurses involves letting them “practice in accordance with their 
professional training” (p. xii).  With its emphasis on healthcare policy, leadership, collaboration, 
and systems theory, the DNP degree takes this training and expertise beyond the individual level 
to the systems level, so as to benefit not just the individual patients, but the system that must care 
for them. 
The Urgency of System Change 
It’s not only important to note what the single best change from the status quo is, it’s also 
critically important to understand its urgency, for intermingled moral and economic reasons.  
When postoperative pain is inadequately treated, it intensifies patient physiological responses, 
which may in turn lead to serious complications.  
And as is genuinely self-evident but so often neglected (if impossible to truly forget), 
needless pain needs to be stopped simply because it is needless pain, even if there were no other 
health or economic benefits.  When improperly managed, perioperative pain can easily become 
severe; pain can render one’s life truly miserable, to the point even of making death emotionally 
preferable to life.  Unrelieved pain is not simply a private tragedy—it is socially unjust and 
professionally unethical. 
CRNAs equipped with the DNP have both the nursing experience and systems change 
theory, informed by social justice and leading nursing and leadership thought, to successfully 
systemically champion the needs of those individuals and groups who are currently 
marginalized—most particularly, the opioid tolerant patient—resulting not just in ad hoc 
improvements, but improvements that persist and pervade the entire organization. 




This study adds to the body of literature concerning CRNA pain management knowledge 
and practice patterns related to opioid tolerant patients, providing baseline evidence of CRNA 
self-perceptions of pain management practices and raising awareness in the professional body 
that will lead to systems change in the form of educational development and professional 
guidelines, improving the subjective experience and measurable outcomes when perioperatively 
managing the pain of such vulnerable patients. 
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Appendix A: CRNA Pain-Management Survey Questionnaire 
1. Are you currently practicing as a CRNA? 
a. Yes (continue with survey) 
b. No (exit survey) 
2. Do you personally assess your patients for their history of opioid use or tolerance? 
a. Yes 
b. No 
3. About what percentage (0-100) of your patients are opioid tolerant? ___ 
 
If the above percentage > 1%, then answer the following 3 questions: 
4. How often do you alter your pain management modalities for your patients with a history 






5. When dealing with patients with a history of opioid usage, do you make calculations to 










6. In approximately what percentage (0-100) of opioid tolerant cases do you include adjunct 
pain medications during your intraoperative pain management?  ___ 






8. Does your institution/primary place of employment have inpatient acute pain services to 
follow up on pain management of opioid tolerant patients? 
a. Yes 
b. No 
c. Don’t know 
9. Do you have a collaborative practice in pain management with an anesthesiologist? 
a. Yes 
b. No 
10. If you work in a collaborative practice in your primary place of employment, are you the 










f. I do not work in a collaborative practice. 
11. Have you had any continuing education units (CEUs) related to pain management for 
opioid tolerant patients? 
a. Never 
b. Yes, within the last 2 years 
c. Yes, more than 2 years ago 





The following questions refer to the barriers to providing optimum pain relief for opioid 
tolerant patients.  For each of the following four items, do you agree or disagree that in your own 
practice it is a barrier to optimal pain management with respect to opioid tolerant patients? 
 
1. Fear of addiction 
a. Strongly disagree 
b. Disagree 
c. Neither agree or disagree 
d. Agree 
e. Strongly agree 
2. Respiratory depression 




a. Strongly disagree 
b. Disagree 
c. Neither agree or disagree 
d. Agree 
e. Strongly agree 
3. Lack of CRNA autonomy 
a. Strongly disagree 
b. Disagree 
c. Neither agree or disagree 
d. Agree 
e. Strongly agree 
4. Lack of specific pain guidelines for opioid tolerant patients 
a. Strongly disagree 
b. Disagree 
c. Neither agree or disagree 
d. Agree 
e. Strongly agree 
5. Are there any other barriers you encounter in managing the pain of opioid tolerant 
patients? 
a. Yes 
i. Please describe any other barriers: _____________________ 
b. No 
 





1. What is your age? ____________________ 
2. What is your highest level of education as a CRNA? 
a. Certificate 
b. Bachelors of Science 
c. Masters in Nursing Anesthesia 
d. Doctorate 
3. How many years have you practiced as a CRNA? ___________________ 
4. What is your current employment status? 
a. Full time 
b. Part time 





6. Which best describes your clinical setting? 




e. Free-standing ambulatory center 




Appendix B: Survey Informed Consent 
Rebecca King MNA-CRNA, DNP-student invites you to participate in this research 
study. 
Title: OPIOID TOLERANCE: SELF-PERCEPTION OF PAIN MANAGEMENT OF 
THE OPIOID TOLERANT PATIENT--A SURVEY OF CERTIFIED REGISTERED NURSE 
ANESTHETISTS 
The purpose of this study is to investigate and analyze Certified Registered Nurses 
Anesthetist (CRNA) self-perceived pain management of the opioid tolerant patient.  To 
accomplish this, the researcher will use a quantitative design.  The survey will evaluate the 
participants’ perceptions of pain management of opioid tolerant patients via survey questions 
with Likert scale responses.  This will illuminate our understanding of CRNA care for this 
clinically challenging patient group. 
Your participation in this study should take less than 10 minutes. Completing this survey, 
constitutes  your informed consent to participate in the study. The surveys will be kept 
anonymous. All results will be reported in aggregate rather than individual form. The compiled 
results of the study may be published in scientific research journals or presented at professional 
conferences but will not contain individually identifiable information.  
The risks to you as a participant are minimal. Your participation in the study is voluntary 
and will in no way affect your status as a Certified Registered Nurse Anesthetist (CRNA) or 
membership with the AANA. The AANA will not provide your name or E-mail address to the 
primary investigator. The loss-of-anonymity risk will be minimized by not collecting identifiers.  
The results of the survey will be provided to the principle investigator in an Excel file and will 
not be correlated to identify you. 




There are no known benefits to you of participation in this study. Your participation may 
benefit others in society and CRNA practice generally because it may illuminate the need for a 
systems change in pain management of the opioid tolerant patient. 
You can choose not to participate. If you decide not to participate, there will not be a 
penalty or loss of any benefits to which you are otherwise entitled. 
If you have any questions about this research study, you can call Rebecca King at 507-
287-0513 or Dr. Margaret Dexheimer Pharris at (651) 690-6572.  If you have any questions 
about your rights as a research participant, you can call the Institutional Review Board (IRB) at 
St. Catherine University at (651) 690-6591.  
 
